Open beta · everything is free with an account while we build. Founding accounts get preferred pricing when paid plans arrive. Create yours →
GP

GAVIN PROFFITT

ABBVIE, INC. · Washington, DC
Registered · LDAActive
Request introduction →Claim this profile →

At a glance

Works on
Copyright/Patent/TrademarkHealth IssuesLabor Issues/Antitrust/WorkplaceMedicare/MedicaidTaxation/Internal Revenue CodeTrade (domestic/foreign)
Professional highlights appear here once this profile is claimed. Claim it →

Background

Career
ABBVIE, INC.
Washington, DC · current
Government experience
Professional Staff Member (6/2018-1/2020) for the House Republican Study Committee; Professional Staff member (2/2023-6/2025) for the House Committee on Energy and Commerce; Health Policy Advisor (6/2025-4/2026) for Senator Ron Johnson
Covered official positions, as disclosed on federal filings

The past 12 months

Clients
1
past 12 months
Filings
1
past 12 months
Agencies contacted
Commerce, Dept of (DOC)HOUSE OF REPRESENTATIVESHealth & Human Services, Dept of (HHS)Office of Management & Budget (OMB)SENATETreasury, Dept ofU.S. Trade Representative (USTR)

Specific issues

H.R. 1328, Supply Chain Security and Growth Act of 2025 H.R. 1990, American Innovation and R&D Competitiveness Act of 2025 Public Law No: 119-21 (formerly known as H.R. 1, One Big Beautiful Bill Act) Implementation Public Law 115-97 (formerly known as H.R. 1, Tax Cuts and Jobs Act) Implementation Policy proposals relating to economic activity in Puerto Rico International tax issues, including OECD digital taxation work program
Taxation/Internal Revenue Code · 2026 Q2
Issues related to antitrust and competition policy
Labor Issues/Antitrust/Workplace · 2026 Q2
Issues related to pharmaceutic tariffs and unfair trade practices Issues related to U.S. biotech competitiveness with China
Trade (domestic/foreign) · 2026 Q2
Public Law 117-169 (formerly known as H.R. 5376, Inflation Reduction Act) Implementation regarding Medicare Part D drug negotiation program Policy Proposals related to Medicare Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Issues related to HCV treatment
Medicare/Medicaid · 2026 Q2
S. 864, HELP Copays Act H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act S. 2903, Safe Step Act H.R. 5509, Safe Step Act Drug cost and pricing policy issues Patient affordability issues Issues related to the 340B program Issues related to data privacy Issues related to Hepatitis C elimination Issues related to FDA communications
Health Issues · 2026 Q2
S.1040, Drug Competition Enhancement Act Patent litigation reform issues and issues related to post-grant proceedings at the USPTO Value of intellectual property
Copyright/Patent/Trademark · 2026 Q2

Clients

ABBVIE INC.
2026 · 1 filing
$██,███ / qtrFree in beta

Sources

This profile is built from the public record: filings in the U.S. Senate Lobbying Disclosure Act system. lda.senate.gov ↗

Recent filings1
2026 Q2
ABBVIE INC.
Q2lda.gov →